Achieve Life Sciences, Inc.

Aktienanalyse zu Achieve Life Sciences, Inc. (QUIT)

$6.060

-0.249 (-4.11%)Zum Schluss

Loading chart…
Hoch
6.330
Eröffnung
6.160
Volumengewichteter Durchschnittskurs
6.14
Volumen
822.53K
Marktkap.
—
Tief
6.037
Umsatz
5.05M
EV/EBITDA, TTM
0.00

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

KI-Analyse of Achieve Life Sciences, Inc. (QUIT)

Kaufen

BDJ is a good buy right now due to its attractive 8.1% dividend yield and a solid 32% increase in dividends over the past decade, indicating strong income potential. Additionally, it is currently trading at an 8.2% discount, which could lead to price appreciation as market confidence improves. The main risk is its recent performance with a 1-day change of -0.31%, suggesting some short-term volatility.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Achieve Life Sciences, Inc. (QUIT) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von .

Erwartetes KGV

5J-Durchschnitt P/E
Aktuelles P/E
0.00

Erwartetes EV/EBITDA

5J-Durchschnitt EV/EBITDA
Aktuelles EV/EBITDA
0.00

Erwartetes KUV

Stark unterbewertet
5J-Durchschnitt P/S
20.19
Aktuelles P/S
20.19
Überbewertet
20.19
Unterbewertet
20.19

Whales, die QUIT halten

T

TPG Capital, L.P.

+ HältQUIT

+27.03%

3-Monats-Rendite

L

Logos Global Management, L.P.

+ HältQUIT

+24.07%

3-Monats-Rendite

P

Paradigm Biocapital Advisors LP

+ HältQUIT

+19.24%

3-Monats-Rendite

F

Frazier Life Sciences Management, LP

+ HältQUIT

+10.54%

3-Monats-Rendite

V

VR Management, LLC

+ HältQUIT

+9.81%

3-Monats-Rendite

QUIT FAQ – beantwortet von Alphio AI

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

BDJ is a good buy right now due to its attractive 8.1% dividend yield and a solid 32% increase in dividends over the past decade, indicating strong income potential. Additionally, it is currently trading at an 8.2% discount, which could lead to price appreciation as market confidence improves. The main risk is its recent performance with a 1-day change of -0.31%, suggesting some short-term volatility.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln